![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The Pharmaceutical Industry is currently undergoing a period of rapid change as the pressures of the financial markets highlight fundamental inefficiencies in the current business model. The Achilles heel for the industry is the unacceptable level of attrition in clinical drug development. An imperative for the industry is to reduce the cost and increase the efficiency of Research and Development (R&D). This article provides an analysis of cancer drugs dropped from the industry pipeline in 2010 and offers a perspective on how the future oncology drug pipeline might evolve.
Keywords:
- Ad-IFN gamma
- amsilarotene
- AR-726
- aroplatin
- ASP-0265
- AZD-0530
- bardoxalone
- BIM-23A760
- CGP-47905
- CP-870893
- drozitumab
- efungumab
- galiximab
- GDC-0152
- golgnerminogene pradenovac
- GSK-184072
- IDEC-114
- JNJ-26854165
- KW-2449
- MYC-124
- neuradiab
- NRX-4204
- patupilone
- PF-3814735
- PF-477736
- PF-4929113
- PF-5208766
- resveratrol
- RG-4733
- RG-7419
- RG-7425
- RTA-401
- saracatinib
- serdemetan
- SGI-1776
- SRT-501
- SU-14813
- TAC-101
- TAK-683
- TAS-109
- TG-1042
- TNFerade